MEDIA COVERAGE

06/26/2025

Crain’s Cleveland Business: The U.S. Is Losing Its Biotech Edge

Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, and...
READ THE ARTICLE
06/06/2025

Crain’s Cleveland Business: Cleveland biotech company secures $2.7M in NIH funding

Lamassu Biotech, a company with its “second headquarters” in Cleveland, has received a $2.7 million grant from the National Institutes of Health (NIH). The funds will help support the development...
READ THE ARTICLE
06/04/2025

Cleveland Business Journal: Lamassu Biotech’s dog treatment could lead to human pancreatitis breakthrough, backed by NIH funds

Lamassu Biotech, the North Carolina-based biopharmaceutical company that opened a Cleveland office last year, has received a $2.7 million grant from the National Institutes of Health to help develop its therapy for...
READ THE ARTICLE
04/08/2025

The Washington Times: Biotech should take a page from Elon Musk’s playbookThe Washington Post:

Innovation has always been the foundation of progress, but how we innovate matters as much as the results we achieve. Recent breakthroughs in aerospace and artificial intelligence prove that massive...
READ THE ARTICLE
11/05/2024

Cleveland.com: Biotech startup Lamassu, Cleveland Clinic aim to treat rare cancers with just three pills a month

CLEVELAND, Ohio — A biotech startup from North Carolina thinks Cleveland is where it will develop how to treat rare cancers with just three pills a month. If effective, Lamassu Biotech’s innovative...
READ THE ARTICLE
09/23/2024

RealClear Health: Harris, Trump Must Tackle the Root Causes of High Drug PricesRealClear Health:

One of the most urgent challenges facing the American healthcare system is the complex and multifaceted issue of drug pricing. Like addressing a chronic disease, where treatment must go beyond...
READ THE ARTICLE
08/06/2024

Newsmax Magazine: New Approach to Cancer Treatment

A new type of cancer drug could transform the treatment for many deadly cancers, especially those that have advanced or metastasized and do not respond to other therapies. Rather than...
READ THE ARTICLE
07/12/2024

Cleveland Plains Dealer: Cancer Moonshot Requires More than Money 

Few challenges loom larger for humanity than the fight against cancer. Cancer is an adversary that demands an approach that harnesses the latest technology and the best instincts of the...
READ THE ARTICLE
06/14/2024

Pharma Exec: Lamassu Pharma Bridges Scientific Knowledge and Patient Care

In the realm of drug development, the industry puts a great deal of emphasis on centering the patient experience. As a result, it is imperative that drug developers consider how...
READ THE ARTICLE
05/21/2024

Crain’s Cleveland Business: Lamassu Biotech expanding corporate offices to Cleveland

A North Carolina biotech research firm is expanding its novel therapeutic and drug development efforts to Cleveland. Lamassu Biotech said it's launching corporate offices in the city. The company is...
READ THE ARTICLE
05/16/2024

NEOtrans blog: Biotech startup moving HQ to Cleveland

A partnership with the Cleveland Clinic has prompted a four-year-old biotech startup to relocate its headquarters to Cleveland from Durham, NC, one of the points of the Research Triangle. However, Lamassu...
READ THE ARTICLE
08/05/2020

Bio-IT World: Follow the Money: Cash for AI Models, Oncology, Hematology Therapies

Sema4 gets $121M to build dynamic models of human health and define optimal, individualized health trajectories. Glioblastoma, hematology, and acute pancreatitis all see new funding for therapy development. And AI-powered models net cash.    $1.5M:...
READ THE ARTICLE
03/30/2020

Healthcare Boss: Jason A. Duprat Speaks with Lamassu CEO Dr. Gabi Hanna MD About Navigating Intellectual Property & Entrepreneurship

Dr. Gabi Hanna, a physician entrepreneur with more than 15 years of leadership experience in early drug development and the Executive Director at Duke Preclinical Translational Research Unit speaks with...
READ THE ARTICLE